Amgen Inc (AMGN) Stock Analysis
Verdict: HOLD
Investment score: 62/100
Analysis as of
Is Amgen Inc stock worth reviewing? AI model thesis
Amgen presents a stable, dividend-paying profile with strong execution in its pipeline, balanced by a levered balance sheet and lack of near-term valuation catalysts.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 75/100 (weight 15%)
Amgen Inc opportunities and risks
What speaks for AMGN
- Earnings Execution
What speaks against AMGN
- High Leverage Profile
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AMGN | 24.0x | 5.0x | 13.4x | 71.5% | 20.9% | 4.6% |
| ABBV | 103.0x | 6.0x | 24.4x | 73.5% | 5.8% | 5.0% |
| GILD | 19.1x | 5.5x | 13.9x | 80.8% | 28.9% | 5.8% |
| Peer median | 61.1x | 5.7x | 19.1x | 77.1% | 17.3% | 5.4% |
Frequently asked questions about Amgen Inc (AMGN)
Is AMGN stock a good investment?
The cached TradeMates AI model rates Amgen Inc as HOLD with an investment score of 62/100. Amgen presents a stable, dividend-paying profile with strong execution in its pipeline, balanced by a levered balance sheet and lack of near-term valuation catalysts. This is algorithmic model output, not personal investment advice.
Is AMGN stock a buy?
The TradeMates model verdict for AMGN is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.